Moderna: new positive data for Omicron

(CercleFinance.com) - The biotech group Moderna announces new clinical data on its bivalent Covid-19 booster candidate, mRNA-1273.
214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern.

A booster dose of 50 μg of mRNA-1273.214 met all predefined endpoints, including a superior neutralising antibody response against Omicron one month after administration, compared to the original mRNA-1273 vaccine.

The safety and tolerability profile of mRNA-1273.214 is consistent with the previous mRNA-1273 booster dose. A regulatory submission is expected in the coming weeks to enable its use this autumn.


Copyright (c) 2022 CercleFinance.com. All rights reserved.